Nutraceutical International Corp. was founded in 1993 and is based in Park City, Utah. Nutraceutical International Corporation engages in the manufacture, marketing, distribution, and retail of branded nutritional supplements and other natural products in the United States and internationally. The company offers vitamins and minerals, herbs, specialty formulas, personal care products, homeopathics, functional foods, and other products in various formulations and delivery forms, including capsules, tablets, softgels, chewables, liquids, creams, sprays, powders, and whole herbs. It also publishes, prints, and markets a line of books and booklets to book distributors, national retail bookstores, and health and natural food stores; distributes branded products of certain third parties; and owns neighborhood natural food markets and health food stores. Nutraceutical International sells its products primarily to and through domestic health and natural food stores.

Established in 2004, Merrion operates offices in North Carolina and Ireland. Merrion Pharmaceuticals wants to make complicated drug dosing regimens easier to swallow. A specialty pharmaceutical firm, Merrion develops (independently and in collaboration with other drug companies) oral drugs to replace already-approved injectable-only medicines. Using its patented drug delivery technologies, Merrion's Gastrointestinal Permeation Enhancement Technology (GIPET) improves the absorption of drugs into the blood stream. Its Gastrointestinal Retention System (GIRES) helps the stomach retain drugs, allowing for their extended, controlled release. The company has four candidates in the development pipeline.

Experimental and Applied Sciences (EAS) makes and distributes dietary supplements and weight-management products worldwide. The firm's shakes, nutrition bars, protein drinks, and nutritional supplements -- branded as AdvantEdge, Catapult, EAS, Muscle Armor, and Myoplex -- fuel dieters, body builders, and other athletes. EAS also sells training and exercise videos as well as best-selling book, Body for Life (written by one-time owner Bill Phillips). EAS is part of Abbott Nutrition, a division of leading health care products maker Abbott Laboratories.

The biopharmaceutical company develops cholesterol-lowering drugs for the treatment of cardiovascular and metabolic disease, specifically targeting elevated LDL (low-density lipoprotein, also known as "bad" cholesterol) levels. Its flagship products - experimental drugs AEGR-733 and AEGR-427 - are MTP (microsomal triglyceride transfer protein) inhibitors, drugs which block a protein that incites cholesterol production in the liver and intestine. Cutting LDL levels may add years to patients' lives but must be weighed against potential side effects such as fat accumulation in the liver, which can lead to inflammation, scarring, and cirrhosis.

Don and Lucy Hillestad founded Hillestad Pharmaceuticals USA, Inc. in 1959. Hillestad Pharmaceuticals USA goes natural, producing vitamin, mineral, protein, and herb products from all-natural sources. It also makes prescription and nonprescription vitamin products for dialysis patients under the Dialyvite and Hill*Vite names. In addition, Hillestad offers private-label manufacturing of tablets, powders, cremes, lotions, and liquids for doctors and pharmacies, health food stores, and various national and international companies.

Spherotech, Inc. company was founded in 1992. pherotech is very particular about its business. Spherotech company manufactures microparticles for the drug and medical device industries. Its product offerings include ferromagnetic, fluorescent, latex, paramagnetic, and various colored microparticles. Spherotech's products are used in applications such as fluorescence and enzyme immunoassay.

The German drug company -- seller of popular over-the-counter remedies Zantac and Dulcolax, as well as prescription Flomax for enlarged prostate -- makes a host of prescription and OTC products, not to mention fine chemicals and pet medications. Its prescription drugs include treatments for respiratory ailments, hypertension, HIV, and depression. Boehringer also offers cold, gastrointestinal, and pain remedies, as well as vaccines, drugs, and nutritionals for farm animals and pets. The company operates worldwide. The founding Boehringer family controls the company through parent company C.H. Boehringer Sohn.

CytRx Corporation company was founded in 1985 and is headquartered in Los Angeles, California. CytRx Corporation, a biopharmaceutical research and development company, engages in the development of human therapeutics. Its product pipeline includes Tamibarotene, a synthetic retinoid in Phase II clinical development to treat acute promyelocytic leukemia; INNO-2006, a pro-drug for doxorubicin in Phase II clinical development for the treatment of cancer; Bafetinib, a drug in Phase I clinical development to treat chronic myeloid leukemia; Arimoclomol, an orally-administered small-molecule product candidate in Phase IIb clinical development for the treatment of amyotrophic lateral sclerosis; and Iroxanadine, an orally-administered small-molecule product candidate in Phase I clinical development to treat diabetic ulcers. The company also engages in developing treatments for neurodegenerative and other disorders based on its small-molecule molecular chaperone amplification technology; and new-drug discovery research utilizing its master chaperone regulator assay technology.

Babraham Bioscience Technologies (BBT) is the operating company of the Babraham Institute, which works with companies around the world on pharmaceutical and biotechnology research projects. The company is committed to fostering innovation and bridging the gap from research to daily application. Through Babraham Technix, the company provides financial and administrative services to start-up biotech companies. It gives special emphasis to companies emerging from its Babraham Bioincubator division, which supports companies that research the role of genomics in healthcare. Commercial spin-offs from BBT include Discerna Ltd. and Orla Protein Technologies.

Adherex Technologies researches and develops cancer treatments. One of its lead drug candidates targets a tumor's blood supply and makes those blood vessels weak and leaky by disrupting a key protein. Other potential therapies could make cancer cells more vulnerable to anti-cancer drugs or help prevent hearing loss in children undergoing certain types of chemotherapy. Adherex Technologies' pipeline is strongly based on compounds that disrupt cadherins, proteins that adhere like molecules together in cell adhesion. Southpoint Capital Advisors own a controlling stake in the company.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.